Duncan Hewett

Dr Duncan Hewett

NHMRC Grant-Funded Researcher (B)

School of Pharmacy and Biomedical Science

College of Health

Eligible to supervise Masters and PhD - email supervisor to discuss availability.

Dr Duncan Hewett is a senior postdoctoral scientist in the Myeloma Research Group of Dr Kate Vandyke. He is located within the Precision Cancer Medicine Theme at SAHMRI on North Terrace. Multiple Myeloma is a largely incurable haematological cancer caused by the clonal expansion of differentiated B cells called plasma cells. His research focuses on using cell-based and mouse-based models of multiple myeloma to more fully understand the roles that mutated or dysregulated genes play in cancer initiation and progression, and to test the pre-clinical efficacy of novel anti-myeloma therapeutics.

Current projects include: (a) the use of in vivo genetic screens using CRISPR-Cas9 and metabolomics to identify previously unknown mechanisms promoting myeloma tumour cell survival within the bone marrow microenvironment; (b) the optimisation of lenalidomide drug responsive mouse models of myeloma to search for new drug synergies and boost host immune responses to tumours. 

Opportunities exist in Semester 1 2025 for Honours and/or HDR projects for new students across many aspects of the above projects. Please contact me via email to discuss further and/or arrange a visit to our laboratory located within the Precision Cancer Medicine Theme in the South Australian Health and Medical Research Institute (SAHMRI).

 

 

 

 

 

Year Citation
2025 Plakhova, N., Panagopoulos, V., Cantley, M. D., Trainor, L. J., Hewett, D. R., Clark, K. C., . . . Vandyke, K. (2025). Age-related mesenchymal stromal cell senescence is associated with progression from MGUS to multiple myeloma.. Leukemia, 39(6), 1464-1475.
DOI Scopus1 WoS3 Europe PMC1
2025 Clark, J. R., Panagopoulos, V., Noll, J. E., Mrozik, K. M., Bradey, A. L., Croucher, P. I., . . . Hewett, D. R. (2025). Mer receptor expression promotes multiple myeloma disease development via a cell-extrinsic mechanism. Experimental Hematology, 150(ARTN 104842), 1-15.
DOI
2024 Zeissig, M. N., Hewett, D. R., Mrozik, K. M., Panagopoulos, V., Wallington-Gates, C. T., Spencer, A., . . . Zannettino, A. C. W. (2024). Expression of the chemokine receptor CCR1 decreases sensitivity to bortezomib in multiple myeloma cell lines. Leukemia Research, 139, 107469-1-107469-8.
DOI Scopus7 WoS6 Europe PMC6
2023 Williams, C. M. D., Noll, J. E., Bradey, A. L., Duggan, J., Wilczek, V. J., Masavuli, M. G., . . . Panagopoulos, V. (2023). Myeloperoxidase creates a permissive microenvironmental niche for the progression of multiple myeloma. British Journal of Haematology, 203(4), 614-624.
DOI Scopus5 WoS5 Europe PMC4
2020 Friend, N., Noll, J. E., Opperman, K. S., Clark, K. C., Mrozik, K. M., Vandyke, K., . . . Zannettino, A. C. W. (2020). GLIPR1 expression is reduced in multiple myeloma but is not a tumour suppressor in mice. PLoS One, 15(1), e0228408-1-e0228408-25.
DOI Scopus3 WoS14 Europe PMC3
2020 Cheong, C. M., Mrozik, K. M., Hewett, D. R., Bell, E., Panagopoulos, V., Noll, J. E., . . . Vandyke, K. (2020). Twist-1 is upregulated by NSD2 and contributes to tumour dissemination and an epithelial-mesenchymal transition-like gene expression signature in t(4;14)-positive multiple myeloma. Cancer letters, 475, 99-108.
DOI Scopus27 WoS27 Europe PMC25
2020 Mrozik, K. M., Cheong, C. M., Hewett, D. R., Noll, J. E., Opperman, K. S., Adwal, A., . . . Zannettino, A. C. W. (2020). LCRF-0006, a small molecule mimetic of the N-cadherin antagonist peptide ADH-1, synergistically increases multiple myeloma response to bortezomib.. FASEB Bioadv, 2(6), 339-353.
DOI Scopus5 WoS6 Europe PMC9
2020 Clark, K. C., Hewett, D. R., Panagopoulos, V., Plakhova, N., Opperman, K. S., Bradey, A. L., . . . Zannettino, A. C. W. (2020). Targeted disruption of bone marrow stromal cell-derived Gremlin1 limits multiple myeloma disease progression in vivo. Cancers, 12(8), 2149-1-2149-20.
DOI Scopus10 WoS10 Europe PMC9
2020 Friend, N. L., Hewett, D. R., Panagopoulos, V., Noll, J. E., Vandyke, K., Mrozik, K. M., . . . Zannettino, A. C. W. (2020). Characterization of the role of Samsn1 loss in multiple myeloma development. FASEB BioAdvances, 2(9), 554-572.
DOI Scopus7 WoS6 Europe PMC8
2020 Zeissig, M. N., Hewett, D. R., Panagopoulos, V., Mrozik, K. M., To, L. B., Croucher, P. I., . . . Vandyke, K. (2020). Expression of the chemokine receptor CCR1 promotes the dissemination of multiple myeloma plasma cells in vivo. Haematologica, 106(12), 3176-3187.
DOI Scopus22 WoS22 Europe PMC19
2019 Khoo, W. H., Ledergor, G., Weiner, A., Roden, D. L., Terry, R. L., McDonald, M. M., . . . Croucher, P. I. (2019). A niche-dependent myeloid transcriptome signature defines dormant myeloma cells. Blood, 134(1), 30-43.
DOI Scopus116 WoS110 Europe PMC106
2019 Opperman, K. S., Vandyke, K., Clark, K. C., Coulter, E. A., Hewett, D. R., Mrozik, K. M., . . . Zannettino, A. C. (2019). Clodronate-liposome mediated macrophage depletion abrogates multiple myeloma tumor establishment in vivo. Neoplasia, 21(8), 777-787.
DOI Scopus65 WoS62 Europe PMC54
2019 Dutta, A., Fink, J., Grady, J., Morgan, G., Mullighan, C., To, L., . . . Zannettino, A. (2019). Subclonal evolution in disease progression from MGUS/SMM to multiple myeloma is characterised by clonal stability. Leukemia, 33(2), 457-468.
DOI Scopus105 WoS105 Europe PMC97
2018 Dutta, A. K., Hewett, D. R., Fink, J. L., & Zannettino, A. C. W. (2018). Using genomics to better define high-risk MGUS/SMM patients. Oncotarget, 9(93), 36549-36550.
DOI Scopus2 Europe PMC2
2017 Wallington-Beddoe, C., Bennett, M., Vandyke, K., Davies, L., Zebol, J., Moretti, P., . . . Pitson, S. (2017). Sphingosine kinase 2 inhibition synergises with bortezomib to target myeloma by enhancing endoplasmic reticulum stress. Oncotarget, 8(27), 43602-43616.
DOI Scopus42 WoS40 Europe PMC36
2017 Dutta, A., Hewett, D., Fink, J., Grady, J., & Zannettino, A. (2017). Cutting edge genomics reveal new insights into tumour development, disease progression and therapeutic impacts in multiple myeloma. British Journal of Haematology, 178(2), 196-208.
DOI Scopus19 WoS17 Europe PMC15
2017 Vandyke, K., Zeissig, M., Hewett, D., Martin, S., Mrozik, K., Cheong, C., . . . Zannettino, A. (2017). HIF-2α promotes dissemination of plasma cells in multiple myeloma by regulating CXCL12/CXCR4 and CCR1. Cancer Research, 77(20), 5452-5463.
DOI Scopus50 WoS47 Europe PMC44
2017 Hewett, D., Vandyke, K., Lawrence, D., Friend, N., Noll, J., Geoghegan, J., . . . Zannettino, A. (2017). DNA barcoding reveals habitual clonal dominance of myeloma plasma cells in the bone marrow microenvironment. Neoplasia : An International Journal for Oncology Research, 19(12), 972-981.
DOI Scopus18 WoS17 Europe PMC16
2015 Cheong, C., Chow, A., Fitter, S., Hewett, D., Martin, S., Williams, S., . . . Vandyke, K. (2015). Tetraspanin 7 (TSPAN7) expression is upregulated in multiple myeloma patients and inhibits myeloma tumour development in vivo. Experimental Cell Research, 332(1), 24-38.
DOI Scopus36 WoS36 Europe PMC35
2015 Mrozik, K., Cheong, C., Hewett, D., Chow, A., Blaschuk, O., Zannettino, A., & Vandyke, K. (2015). Therapeutic targeting of N-cadherin is an effective treatment for multiple myeloma. British Journal of Haematology, 171(3), 387-399.
DOI Scopus31 WoS29 Europe PMC28
2015 Noll, J., Vandyke, K., Hewett, D., Mrozik, K., Bala, R., Williams, S., . . . Zannettino, A. (2015). PTTG1 expression is associated with hyperproliferative disease and poor prognosis in multiple myeloma. Journal of Hematology and Oncology, 8(1), 106-1-106-16.
DOI Scopus35 WoS35 Europe PMC33
2014 Noll, J., Hewett, D., Williams, S., Vandyke, K., Kok, C., To, L., & Zannettino, A. (2014). SAMSN1 is a tumor suppressor gene in multiple myeloma. Neoplasia, 16(7), 572-585.
DOI Scopus41 WoS39 Europe PMC42
2010 Melo, J. V., & Hewett, D. R. (2010). Wrapping BCR-ABL: It's in the bag. Blood, 116(18), 3382-3383.
DOI Scopus2
2010 Barlow, J., Drynan, L., Hewett, D., Holmes, L., Lorenzo-Abalde, S., Lane, A., . . . McKenzie, A. (2010). A p53-dependent mechanism underlies macrocytic anemia in a mouse model of human 5q- syndrome. Nature Medicine, 16(1), 59-66.
DOI Scopus306 Europe PMC257
2008 Hiwase, D., Saunders, V., Hewett, D., Frede, A., Zrim, S., Dang, P., . . . White, D. (2008). Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications. Clinical Cancer Research, 14(12), 3881-3888.
DOI Scopus168 WoS152 Europe PMC140
2006 Fallon, P. G., Ballantyne, S. J., Mangan, N. E., Barlow, J. L., Dasvarma, A., Hewett, D. R., . . . McKenzie, A. N. J. (2006). Identification of an interleukin (IL)-25-dependent cell population that provides IL-4, IL-5, and IL-13 at the onset of helminth expulsion. Journal of Experimental Medicine, 203(4), 1105-1116.
DOI Scopus646 Europe PMC569
2005 Hewett, D. R., Simons, A. L., Mangan, N. E., Jolin, H. E., Green, S. M., Fallon, P. G., & McKenzie, A. N. J. (2005). Lethal, neonatal ichthyosis with increased proteolytic processing of filaggrin in a mouse model of Netherton syndrome. Human Molecular Genetics, 14(2), 335-346.
DOI Scopus82 Europe PMC65
2002 Hewett, D., Samuelsson, L., Polding, J., Enlund, F., Smart, D., Cantone, K., . . . Purvis, I. (2002). Identification of a psoriasis susceptibility candidate gene by linkage disequilibrium mapping with a localized single nucleotide polymorphism map. Genomics, 79(3), 305-314.
DOI Scopus98 Europe PMC69
2002 Maniatis, N., Collins, A., Xu, C. F., McCarthy, L. C., Hewett, D. R., Tapper, W., . . . Morton, N. E. (2002). The first linkage disequilibrium (LD) maps: Delineation of hot and cold blocks by diplotype analysis. Proceedings of the National Academy of Sciences of the United States of America, 99(4), 2228-2233.
DOI Scopus152 Europe PMC125
2001 McCarthy, L. C., Hosford, D. A., Riley, J. H., Bird, M. I., White, N. J., Hewett, D. R., . . . Purvis, I. J. (2001). Single-nucleotide polymorphism alleles in the insulin receptor gene are associated with typical migraine. Genomics, 78(3), 135-149.
DOI Scopus122 Europe PMC98
2001 McCarthy, L. C., Hosford, D. A., Riley, J. H., Bird, M. I., White, N. J., Hewett, D. R., . . . Purvis, I. J. (2001). Erratum: Single-nucleotide polymorphism alleles in the insulin receptor gene are associated with typical migraine (Genomics (2001) 78 (135-149)). Genomics, 79(2), 271.
DOI
1998 Hewett, D., Handt, O., Hobson, L., Mangelsdorf, M., Eyre, H., Baker, E., . . . Richards, R. (1998). FRA10B structure reveals common elements in repeat expansion and chromosomal fragile site genesis. Molecular Cell, 1(6), 773-781.
DOI Scopus83 WoS77 Europe PMC61
1997 Yu, S., Mangelsdorf, M., Hewett, D., Hobson, L., Baker, E., Eyre, H., . . . Richards, R. (1997). Human chromosomal fragile site FRA16B is an amplified AT-rich minisatellite repeat. Cell, 88(3), 367-374.
DOI Scopus179 WoS166 Europe PMC122
1997 Horwitz, M., Benson, K., Li, F. Q., Wolff, J., Leppert, M., Hobson, L., . . . Raskind, W. (1997). Genetics heterogeneity in familial acute myelogenous leukemia: Evidence for a second locus at chromosome 16q21-23.2. American Journal of Human Genetics, 61(4), 873-881.
DOI Scopus40 WoS34 Europe PMC28

Year Citation
2023 Williams, C., Noll, J., Harnas, D., Parkinson, H., Hewett, D., Wyllie, K., . . . Panagopoulos, V. (2023). Targeted Inhibition of Myeloperoxidase (MPO): A New Therapeutic Strategy for the Treatment of Multiple Myeloma. In BLOOD Vol. 142 (pp. 3 pages). CA, San Diego: AMER SOC HEMATOLOGY.
DOI WoS3
2017 Zeissig, M. N., Hewett, D. R., Martin, S., Mrozik, K. M., Cheong, C. M., Diamond, P., . . . Zannettino, A. C. W. (2017). HIF-2α Upregulates CCR1 to Promote Dissemination of Plasma Cells in Multiple Myeloma. In BLOOD Vol. 130 (pp. 2 pages). Atlanta, GA: AMER SOC HEMATOLOGY.

Year Citation
2023 Parkinson, H., Breen, J., Hin, N., Panagopoulos, V., Zannettino, A., Vandyke, K., & Hewett, D. (2023). A Functional Genomic Screen to Identify Novel Genes Involved in Multiple Myeloma Tumour Development. Poster session presented at the meeting of Abstracts of the 65th Annual Meeting of the American Society of Hematology (ASH), as published in Blood. CA, San Diego: American Society of Hematology.
DOI
2019 Zeissig, M. N., Hewett, D. R., Mrozik, K. M., Panagopoulos, V., Engelhardt, M., To, L. B., . . . Vandyke, K. (2019). Therapeutic Targeting of CCR1 to Prevent Dissemination of Multiple Myeloma Plasma Cells. Poster session presented at the meeting of BLOOD. FL, Orlando: ELSEVIER.
DOI

Year Citation
- Dutta, A., Zannettino, A., Hewett, D., & l.fink@uq.edu.au. (n.d.). ZANNETTINO_EGA DAA_EGAS00001002850.doc.
DOI

Date Role Research Topic Program Degree Type Student Load Student Name
2021 - 2025 Principal Supervisor Targeting the Bone Marrow Microenvironment: Exploring Gremlin1’s Role in Myeloma-Associated Macrophages and Developing IMiD-Sensitive Murine Models of Myeloma Doctor of Philosophy Doctorate Full Time Dr Emma Anna-Jane Cheney
2020 - 2025 Principal Supervisor Identification of novel genes involved in multiple myeloma tumorigenesis Doctor of Philosophy Doctorate Full Time Miss Hayley Bridget Parkinson
2019 - 2023 Co-Supervisor The TAM receptor family in multiple myeloma Doctor of Philosophy Doctorate Full Time Miss Justine Rachel Clark
2017 - 2020 Co-Supervisor CCR1 as a Therapeutic Target in Multiple Myeloma: Preventing Tumour Dissemination and Therapeutic Resistance Doctor of Philosophy Doctorate Full Time Miss Mara Zeissig
2015 - 2019 Co-Supervisor The Role of SAMSN1 in Multiple Myeloma Doctor of Philosophy Doctorate Full Time Ms Natasha Friend
2015 - 2020 Co-Supervisor The Role of Gremlin1 in Multiple Myeloma Doctor of Philosophy Doctorate Full Time Mrs Kimberley Claire Clark
2014 - 2018 Co-Supervisor A Genomic Approach Towards an Understanding of Clonal Evolution and Disease Progression in Multiple Myeloma Doctor of Philosophy Doctorate Full Time Ankit Kumar Dutta
2009 - 2013 Co-Supervisor Regulation of BCR-ABL expression via its 3'untranslated region Doctor of Philosophy Doctorate Full Time Mr Bradley Chereda

Connect With Me

External Profiles

Other Links